On March 18, 2026, Reviva Pharmaceuticals Holdings, Inc. announced a registered public offering of 6,283,334 common shares and warrants, expected to raise approximately $10 million, with net proceeds of about $9 million for research and development, including a Phase 3 trial for schizophrenia. The offering is set to close around March 20, 2026.